Top
This page is only for information of and use by registered medical practitioners. Other persons are advised not to act on the basis of information contained in this page. They are requested to consult registered medical practitioner.

Bisotab (Bisoprolol Fumarate Tablets) is a angiotensin II receptor blocker (ARB) used in the therapy of hypertension, Angina Pectoris, and Congestive Heart Failure. Bisotab is marketed by JB Chemical and Pharmaceuticals limited and comes in two doses namely Bisotab 2.5 mg and Bisotab 5 mg.


Bisoprolol is indicated in the treatment of many conditions including Blood Pressure management, Angina Pectoris and Congestive heart failure. Bisoprolol is a potent highly beta1-selective-adrenoceptor blocking agent, lacking intrinsic sympathomimetic and relevant membrane stabilising activity. As with other Beta1blocking agents, the method of acting in hypertension is unclear. However, it is known that Bisoprolol reduces plasma renin activity markedly.



With regards to its antianginal mechanism, Bisoprolol by inhibiting the cardiac beta receptors inhibits the response given to sympathetic activation. That results in the decrease of heart rate and contractility this way decreasing the oxygen demand of the cardiac muscle.

Overview
Name of Product: BISOTAB* 2.5 / 5
Marketed by : JB Chemicals and Pharmaceuticals Ltd
Medicine composition: Bisoprolol Fumarate IP 2.5 mg / 5mg
Prescription vs.OTC: Prescription by Doctor required
Dosage Form: Film coated tablets

Bisotab 2.5/5mg (Bisoprolol Fumarate) is indicated for the treatment of

  • Hypertension
  • Coronary heart disease (Angina pectoris)
  • Congestive heart failure (CHF)

The dosage and administration of Bisotab in the treatment of hypertension and chronic stable angina pectoris, Stable chronic heart failure including those in special population varies based on the disease and patient condition including special populations.
Please download the complete product Leaflet to See the details on Dosage of Bisotab
Method of Administration: Bisotab tablets are meant for oral use. Bisoprolol tablets should be taken in the morning and can be taken with food. They should be swallowed with liquid and should not be chewed.

Bisoprolol is contra-indicated in patients with:

  • Hypersensitivity to the active substance or to any of the excipients
  • Acute heart failure or during episodes of heart failure decompensation requiring i.v. inotropic therapy
  • Cardiogenic shock
  • Second or third degree AV block (without a pacemaker)
  • Sick sinus syndrome
  • Sinoatrial block
  • Symptomatic bradycardia
  • Symptomatic hypotension
  • Severe bronchial asthma or severe chronic obstructive pulmonary disease
  • Severe forms of peripheral arterial occlusive disease or severe forms of Raynaud's syndrome
  • Untreated phaeochromocytoma
  • Metabolic acidosis
(Download product Leaflet for details on Contraindications)

Bisoprolol is indicated in multiple conditions. In General Bisoprolol must be used with caution in:

  • chronic obstructive lung diseases, which may cause symptoms, bronchodilating therapy is recommended to be given concomitantly. Occasionally an increase of the airway resistance may occur in patients with asthma, therefore the dose of beta2-stimulants may have to be increased
  • Diabetes mellitus with large fluctuations in blood glucose values; symptoms of hypoglycaemia (e.g. tachycardia, palpitations or sweating) can be masked
  • Strict fasting
  • Ongoing desensitisation therapy. As with other beta-blockers, bisoprolol may increase both the sensitivity towards allergens and the severity of anaphylactic reactions. Epinephrine treatment may not always yield the expected therapeutic effect.
  • First degree AV block
  • Prinzmetal's angina
  • Peripheral arterial occlusive disease. Aggravation of symptoms may occur especially when starting therapy.
  • General anaesthesia

Download Leaflet to see the detailed warnings and precautions related to the specific conditions .

Bisoprolol may have drug interactions with the following drugs

  • Calcium antagonists of the dihydropyridine type such as felodipine and amlodipine
  • Class-III antiarrhythmic medicinal product (e.g. amiodarone)
  • Parasympathomimetic medicinal products
  • Topical beta-blocking agents
  • Insulin and oral antidiabetic medicinal products
  • Anaesthetic agents
  • Digitalis glycosides
  • Non-steroidal anti-inflammatory medicinal products (NSAIDs)
  • β-Sympathomimetic agents (e.g. isoprenaline, dobutamine)
  • Sympathomimetics that activate both β- and α-adrenoceptors (e.g. norepinephrine, epinephrine),etc

Download the Product Leaflet, to see the detailed drug interactions.

The most common signs expected with overdose of a beta-blocker such as bisoprolol are bradycardia, hypotension, bronchospasm, acute cardiac insufficiency and hypoglycaemia. There is limited experience with overdose of bisoprolol, only a few cases of overdose with bisoprolol have been reported.

Download the Product Leaflet, to see the the detailed information on the Undesirable Side effects/ Overdose.

Download the Product Leaflet, to see the details on Pharmacodynamic and Pharmacokinetic Properties of Bisotab

Contact us for further information

Bisotab (Bisoprolol Fumarate Tablets) is a angiotensin II receptor blocker (ARB) used in the therapy of hypertension, Angina Pectoris, and Congestive Heart Failure. Bisotab is marketed by JB Chemical and Pharmaceuticals limited and comes in two doses namely Bisotab 2.5 mg and Bisotab 5 mg.


Bisoprolol is indicated in the treatment of many conditions including Blood Pressure management, Angina Pectoris and Congestive heart failure. Bisoprolol is a potent highly beta1-selective-adrenoceptor blocking agent, lacking intrinsic sympathomimetic and relevant membrane stabilising activity. As with other Beta1blocking agents, the method of acting in hypertension is unclear. However, it is known that Bisoprolol reduces plasma renin activity markedly.



With regards to its antianginal mechanism, Bisoprolol by inhibiting the cardiac beta receptors inhibits the response given to sympathetic activation. That results in the decrease of heart rate and contractility this way decreasing the oxygen demand of the cardiac muscle.